Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1/2 Trial of ATEV Conduit for Discontinuous Pulmonary Arteries
NCT07785661Phase 2Not yet recruiting
- Start
- Nov 2026
- Primary completion
- Aug 2030
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of acellular tissue engineered vessel in Pulmonary artery agenesis (PAA). Primary endpoints: Treatment Emergent Adverse Events at 12 months, Survival Rate at 6 and 12 Months Post-Implantation and 3 more. Planned start Nov 2026; status: not yet recruiting.
02
Drugs
acellular tissue engineered vessel
03
Conditions
Pulmonary artery agenesis (PAA)
Beyond the preview
Go deeper on NCT07785661.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07785661.